Peginterferon alfa News and Research

RSS

Weight-based ribavirin undertreats African–American HCV patients

African–Americans with hepatitis C virus genotype 1 infections have lower ribavirin plasma exposures than Caucasian Americans when treated with weight-based ribavirin plus peginterferon.

12 Nov 2012

Telaprevir offers advantages in patients with chronic hepatitis C infection of genotype 1

The drug telaprevir has been available for treatment of chronic hepatitis C infection of genotype 1 since autumn 2011. In an early benefit assessment pursuant to the "Act on the Reform of the Market for Medicinal Products" (AMNOG), the German Institute for Quality and Efficiency in Health Care (IQWiG) examined whether telaprevir offers an added benefit compared with the present standard therapy.

6 Sep 2012

Johnson & Johnson second quarter sales decrease 0.7% to $16.5B

Johnson & Johnson today announced sales of $16.5 billion for the second quarter of 2012, a decrease of 0.7% as compared to the second quarter of 2011. Operational results increased 3.5% and the negative impact of currency was 4.2%.

17 Jul 2012

Medivir, Bristol-Myers Squibb to initiate TMC435 and daclatasvir phase II combination study in HCV

Medivir AB, the research-based pharmaceutical company focused on the development of high-value treatments for infectious diseases, announces that a phase II combination study with the investigational compound TMC435 and Bristol-Myers Squibb's investigational compound daclatasvir will start in July.

29 Jun 2012

HCV suppression reduces liver damage

Profound suppression of the hepatitis C virus reduces long-term hepatic inflammation and fibrosis even in patients who do not achieve a sustained virologic response, research demonstrates.

19 Jun 2012

New research reveals effective treatments for gastrointestinal conditions

New research being presented at Digestive Disease Week- (DDW) reveals effective treatments for a number of gastrointestinal conditions, which are often chronic and costly.

22 May 2012

New data shows consolidation of interferon-free revolution in HCV treatment

New data presented at the International Liver Congress 2012 shows consolidation of the interferon-free (IFN) revolution in HCV treatment. The much anticipated data from a number of clinical trials confirm that combinations of antivirals offer the hope of shorter, more effective treatment with fewer side effects.

20 Apr 2012

Bristol-Myers Squibb announces results from daclatasvir plus asunaprevir Phase II HCV study

Bristol-Myers Squibb Company today announced results from a Phase II study in which treatment with an all-oral, dual direct-acting antiviral (DAA) regimen of daclatasvir, an investigational NS5A replication complex inhibitor, and asunaprevir, an investigational NS3 protease inhibitor, achieved undetectable viral load 24 weeks post-treatment (SVR24) in 77% (33/43) of difficult-to-treat genotype 1b hepatitis C (HCV) patients.

20 Apr 2012

Final results from MSD’s VICTRELIS plus PEGINTRON Phase III trial on HCV treatment-related anemia

MSD, known as Merck in the United States and Canada, announced final results from a Phase III, open-label study designed to compare the impact of two anaemia management strategies on sustained virologic response (SVR) in patients with chronic hepatitis C virus (HCV) genotype 1 infection treated with VICTRELIS(boceprevir) in combination with PEGINTRON and ribavirin.

20 Apr 2012

Alios BioPharma, Vertex initiate ALS-2200 and ALS-2158 clinical study in HCV

Vertex Pharmaceuticals Incorporated and Alios BioPharma, Inc. today announced the initiation of two clinical studies for the nucleotide analogues ALS-2200 and ALS-2158, which are inhibitors of the hepatitis C NS5B polymerase.

12 Dec 2011

Encouraging interim results from daclatasvir Phase IIb study in genotype 1 and 4 HCV patients

Bristol-Myers Squibb Company today announced interim results from a Phase IIb clinical trial (COMMAND-1) of 395 treatment-naïve, genotype 1 and 4 hepatitis C infected patients in which two doses of the investigational NS5A replication complex inhibitor daclatasvir (BMS-790052), in combination with peginterferon alfa and ribavirin (alfa/RBV), achieved higher virologic response rates through Week 12 than the alfa/RBV control group, with comparable rates of adverse events.

9 Nov 2011

Vertex announces positive interim data from INCIVEK Phase 2 combination trial on HIV, HCV

Vertex Pharmaceuticals Incorporated today announced positive interim results from an ongoing Phase 2 study designed to evaluate the safety and tolerability of INCIVEK (telaprevir) tablets in combination with pegylated-interferon and ribavirin in people who are co-infected with chronic genotype 1 hepatitis C (HCV) and human immunodeficiency virus.

7 Nov 2011

Vertex announces 16 grant recipients of Hep-C Circle of Care program

Vertex Pharmaceuticals Incorporated today announced that it has awarded 16 grants totaling approximately $1.5 million to a variety of academic, patient and community groups as part of the Vertex Hep-C Circle of Care program, a pilot competitive grants program designed to foster innovative approaches to patient care and support people living with chronic hepatitis C.

5 Nov 2011

Vertex initiates INCIVEK combination Phase 3b study for hepatitis C

Vertex Pharmaceuticals Incorporated today announced the initiation of a Phase 3b study called CONCISE that will evaluate the potential for treatment with INCIVEK (telaprevir) combination therapy to be shortened to 12 weeks in people with genotype 1 chronic hepatitis C who have the 'CC' variation near the IL28B gene.

24 Oct 2011

Boehringer Ingelheim announces new data from hepatitis C virus portfolio

Boehringer Ingelheim announced today that new data from its hepatitis C virus (HCV) portfolio will be presented in scientific sessions at The Liver Meeting 2011, the 62nd Annual Meeting of the American Association for the Study of Liver Diseases (AASLD), taking place November 4 - November 8 in San Francisco, CA.

22 Oct 2011

Johnson & Johnson third quarter sales increase 6.8% to $16.0 billion

Johnson & Johnson today announced sales of $16.0 billion for the third quarter of 2011, an increase of 6.8% as compared to the third quarter of 2010. Operational results increased 2.6% and the positive impact of currency was 4.2%. Domestic sales declined 3.7%.

18 Oct 2011

Positive data from Anadys' setrobuvir Phase IIb combination study on genotype 1 HCV

Anadys Pharmaceuticals, Inc. today released interim antiviral response and safety data from an ongoing Phase IIb study of setrobuvir in combination with pegylated interferon and ribavirin (P/R) in genotype 1 hepatitis C patients.

14 Oct 2011

Vertex announces availability of INCIVEK to treat hepatitis C in Canada

Vertex Pharmaceuticals Incorporated announced today that INCIVEK (telaprevir) tablets are now available in Canada for people with genotype 1 chronic hepatitis C with compensated liver disease, including cirrhosis.

11 Oct 2011

Bristol-Myers to present abstracts on research in liver disease at The Liver Meeting 2011

Bristol-Myers Squibb Company announced today that 22 abstracts on the Company's research in liver disease have been accepted for presentation at The Liver Meeting 2011, the 62nd annual meeting of the American Association for the Study of Liver Diseases, in San Francisco, November 4 - 8.

1 Oct 2011

New analyses from Phase III studies of VICTRELIS to be presented at AASLD 2011

Merck, known as MSD outside of the United States and Canada, announced today that several new analyses from Phase III studies of VICTRELIS (boceprevir), the company's first-in-class, oral hepatitis C virus NS3/4A protease inhibitor will be presented at the 62nd Annual Meeting of the American Association for the Study of Liver Diseases.

1 Oct 2011

Peginterferon alfa News and Research

Weight-based ribavirin undertreats African–American HCV patients

Telaprevir offers advantages in patients with chronic hepatitis C infection of genotype 1

Johnson & Johnson second quarter sales decrease 0.7% to $16.5B

Medivir, Bristol-Myers Squibb to initiate TMC435 and daclatasvir phase II combination study in HCV

HCV suppression reduces liver damage

New research reveals effective treatments for gastrointestinal conditions

New data shows consolidation of interferon-free revolution in HCV treatment

Bristol-Myers Squibb announces results from daclatasvir plus asunaprevir Phase II HCV study

Final results from MSD’s VICTRELIS plus PEGINTRON Phase III trial on HCV treatment-related anemia

Alios BioPharma, Vertex initiate ALS-2200 and ALS-2158 clinical study in HCV

Encouraging interim results from daclatasvir Phase IIb study in genotype 1 and 4 HCV patients

Vertex announces positive interim data from INCIVEK Phase 2 combination trial on HIV, HCV

Vertex announces 16 grant recipients of Hep-C Circle of Care program

Vertex initiates INCIVEK combination Phase 3b study for hepatitis C

Boehringer Ingelheim announces new data from hepatitis C virus portfolio

Johnson & Johnson third quarter sales increase 6.8% to $16.0 billion

Positive data from Anadys' setrobuvir Phase IIb combination study on genotype 1 HCV

Vertex announces availability of INCIVEK to treat hepatitis C in Canada

Bristol-Myers to present abstracts on research in liver disease at The Liver Meeting 2011

New analyses from Phase III studies of VICTRELIS to be presented at AASLD 2011

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

From Puberty to Menopause: Clue’s CEO, Audrey Tsang on the Power of Femtech

Latest News